For the period from 2010 to 2021, we have observed a phenomenon of life sciences
companies conducting Initial Public Offerings (IPOs) without any assets that have …

Pharmaceutical companies operate in a strictly regulated and highly risky environment in
which a single slip can lead to serious financial implications. Accordingly, the …

Background/Aims: Clinical trials provide an opportunity to identify new treatments and can
offer patients access to treatments otherwise unavailable. However, approximately 10% of …

We propose a methodology to estimate the market value of pharmaceutical drugs. Our
approach combines an event study with a model of discounted cash flows and uses stock …

We investigate the impact of information on biopharmaceutical stock prices via an event
study encompassing 503,107 news releases from 1,012 companies. We distinguish …

Purpose Biotech companies stand as key actors in pharmaceutical innovation. The high risk
and long timelines inherent with their R&D investments might hinder their access to funding …

In the pharmaceutical research and development process, the third phase of clinical trials
involves double-blind trials to mitigate the influence of human subjective awareness on the …

Furthermore, we will elaborate on the practical implications of understanding those drivers of
value inflection. For example, how such insight may inform strategic decisions and help …